Show
Sort by
-
- Journal Article
- A1
- open access
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR : a multicentre, randomised controlled open-label phase II trial
-
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis
-
Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients
-
Radiation-induced oesophagitis in lung cancer patients: is susceptibility for neutropenia a risk factor?
-
No association between TGF-β1 polymorphisms and radiation-induced lung toxicity in a European cohort of lung cancer patients
-
Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy